Floxipar 200 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Sparfloxacin |
| Company | Acme laboratories ltd |
Product Title
- Floxipar Tablets
Categories
- Antibacterial Agents
- Fluoroquinolones
- Respiratory Tract Infections
- Urinary Tract Infections
- Topoisomerase IV Inhibitors
- 4-Quinolone Preparations
- Therapeutic Medications
Description
Floxipar is indicated for the treatment of adults with various infections including community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, chronic obstructive pulmonary disease, acute maxillary sinusitis, urinary tract infections, bacterial prostatitis, bacterial diarrhea, osteomyelitis, tuberculosis, and leprosy.
Color Options
- White
Dosage Form
- Tablet
Dosage Strength
200 mg
Dosage Instructions
- Loading Dose: 2 tablets (400 mg) on the first day
- Maintenance Dose: 1 tablet (200 mg) every 24 hours for 10 days
- Renal Impairment Dose: 1 tablet (200 mg) every 48 hours for 9 days
Mode of Action
Inhibits DNA gyrase and topoisomerase IV, effective against susceptible strains of bacteria in the respiratory and urinary tracts.
Absorption
High oral bioavailability of 92%, unaffected by food, but reduced by concurrent antacid administration.
Distribution
Distributes well into the body with a large volume of distribution, penetrates respiratory tissues and fluids effectively.
Metabolism
Primarily metabolized by liver through phase II glucuronidation, no cytochrome P450 involvement.
Excretion
Excreted in feces (50%) and urine (50%), with approximately 10% unchanged drug excreted in urine.
Interaction
- Chelation complex formation with aluminum and magnesium cations in antacids and sucralfate
- No interaction with theophylline, caffeine, warfarin, cimetidine, or probenecid
- Avoid concomitant use with medications known to prolong the QTc interval
Contraindications
- Hypersensitivity to any ingredient
- Pregnancy and lactation
- Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
- History of Achilles tendinitis following fluoroquinolone use
Side Effects
- Photosensitivity reaction
- Diarrhea
- Nausea
- Headache
- Dyspepsia
- Dizziness
- Insomnia
- Abdominal pain
- Pruritus
- Taste perversion
- QTc interval prolongation
- Vomiting
- Flatulence
- Vasodilatation
Pregnancy & Lactation
Not well studied, should be used during pregnancy only if potential benefit justifies potential risk to the fetus.
Precautions & Warnings
- Discontinue therapy at first signs of phototoxicity reactions
- Safety and effectiveness not established in children, adolescents, pregnant, or lactating women
- Maintain adequate hydration to prevent highly concentrated urine formation
- Administer with caution in renal insufficiency, avoid concomitant use with medications known to prolong QTc interval
- Avoid excessive sunlight exposure
Use in Special Populations
- Geriatric: Pharmacokinetics not altered in elderly with normal renal function
- Pediatric: Pharmacokinetics not studied in pediatric subjects
- Gender: No gender differences observed
- Renal Insufficiency: Plasma concentrations may be higher in patients with renal impairment
- Hepatic Impairment: Pharmacokinetics not altered in patients with mild or moderate hepatic impairment
Storage Conditions
Store below 30°C, away from heat and direct light, out of the reach of children